Search

Search Constraints

You searched for: Author/Creator Phelps, C.

Search Results

1. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL. (23rd June 2022)

2. Pharmacokinetic (PK) profile of quisinostat in combination with gemcitabine and cisplatin in patients (pts) with non-small cell lung cancer (NSCLC) or paclitaxel and carboplatin in pts with NSCLC or epithelial ovarian cancer. (February 2017)

3. Phase I dose-escalation study of the pan-PI3 K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors. (October 2022)

4. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome. (1st July 2016)

5. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome. (2nd June 2016)

6. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome3. (2nd June 2016)